Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...